Millipore Sigma Vibrant Logo
 

06-503


83 Results Advanced Search  
Showing
Documents (80)
Site Content (0)

Narrow Your Results Use the filters below to refine your search

Document Type

  • (37)
  • (16)
  • (15)
  • (12)
Can't Find What You're Looking For?
Contact Customer Service

 
  • Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. 17404311

    Aluminum hydroxide (Alum) is the only adjuvant approved for routine use in humans, although the basis for its adjuvanticity remains poorly understood. In this study, we show that Alum activates caspase-1 and induce secretion of mature IL-1beta and IL-18. Human PBMC or dendritic cells stimulated with pure TLR4 and TLR2 agonists released only traces of IL-1beta or IL-18, despite the fact that the IL-1beta mRNA was readily induced by both TLR agonists. In contrast, cells costimulated with TLR agonists plus Alum released large amount of IL-1beta and IL-18. Alum-induced IL-1beta and IL-18 production was not due to enhancement of TLR signaling but rather reflected caspase-1 activation and in mouse dendritic cells occurred in a MyD88-independent fashion. Secretion of other proinflammatory cytokines such as IL-8 was not affected by Alum treatments. However, TLR-induced production of IL-10 was increased and that of IFN-gamma-inducible protein decreased by Alum cotreatment. Considering the immunostimulatory activities of these cytokines and the ability of IL-1beta to act as adjuvant, our results suggest a mechanism for the adjuvanticity of Alum.
    Document Type:
    Reference
    Product Catalog Number:
    06-503
    Product Catalog Name:
    Anti-Caspase 1 Antibody
  • Membrane localization of the U2 domain of Protein 4.1B is necessary and sufficient for meningioma growth suppression. 15688033

    Meningiomas are common central nervous system tumors; however, the molecular mechanisms underlying their pathogenesis are largely undefined. Previous work has implicated Protein 4.1B as an important tumor suppressor involved in the development of these neoplasms. In this report, we demonstrate that the U2 domain is necessary and sufficient for the ability of Protein 4.1B to function as a meningioma growth suppressor. Using a series of truncation and deletion constructs of DAL-1 (a fragment of Protein 4.1B that retains all the growth suppressive properties), we narrowed the domain required for 4.1B growth suppression to a fragment containing a portion of the FERM domain and the U2 domain using clonogenic assays on meningioma cells. Deletion of the U2 domain in the context of the full-length DAL-1 molecule eliminated growth suppressor function, as measured by thymidine incorporation and caspase-3 activation. Moreover, targeting the U2 domain to the plasma membrane using a membrane localization signal (MLS) reduced cell proliferation, similar to wild-type DAL-1. Collectively, the data suggest that the U2 domain, when properly targeted to the plasma membrane, contains all the residues necessary for mediating Protein 4.1B growth suppression.
    Document Type:
    Reference
    Product Catalog Number:
    06-503
    Product Catalog Name:
    Anti-Caspase 1 Antibody
  • Epidermal growth factor enhances cisplatin-induced apoptosis by a caspase 3 independent pathway. 11391854

    PURPOSE: Activation of the epidermal growth factor (EGF) receptor has previously been shown to increase the sensitivity of cancer cells to DNA-damaging agents, including cisplatin, UV-B, and gamma-radiation. We now investigated the mechanisms by which EGF enhances the sensitivity of human ovarian cancer cells to cisplatin. RESULTS: The effect of EGF on cisplatin sensitivity could not be entirely explained by alterations in the cellular detoxification of cisplatin by glutathione or DNA repair of transcribed genes, as assessed by a plasmid reactivation assay. Furthermore, EGF did not affect the levels of several proteins that regulate apoptotic pathways, including bcl2, bclXL, bax and p53. Cisplatin treatment resulted in activation of caspase 3 and subsequent cleavage of specific substrates containing the DEVD (Asp-Glu-Val-Asp) amino acid sequence, including PARP (poly(ADP-ribose) polymerase). The EGF-mediated increase in cisplatin-induced apoptosis, however, did not result in increased caspase 3 activity. Moreover, apoptosis induced by cisplatin alone was completely inhibited by the caspase 3 inhibitor DEVD-CHO, whereas cell death induced by combined treatment with cisplatin and EGF was not prevented by inhibition of caspase 3. CONCLUSION: Our results suggest that, although cisplatin alone induces apoptosis by a caspase 3 dependent pathway, EGF enhances cisplatin-induced cell death by activating an apoptotic pathway that is independent of caspase 3.
    Document Type:
    Reference
    Product Catalog Number:
    06-503
    Product Catalog Name:
    Anti-Caspase 1 Antibody
  • Caspase-1-mediated regulation of fibrogenesis in diet-induced steatohepatitis. 22411067

    Non-alcoholic steatohepatitis (NASH) is typically associated with pro-apoptotic caspase activation. A potential role for pro-inflammatory caspases remains incompletely understood. Our aims were to examine a potential role of caspase-1 in the development of liver damage and fibrosis in NASH. C57BL/6 wild type (WT) developed marked steatohepatitis, activation, fibrosis and increased hepatic caspase-1 and interleukin-1β expression when placed on the methionine- and choline-deficient (MCD) diet. Marked caspase-1 activation was detected in the liver of MCD-fed mice. Hepatocyte and non-parenchymal fractionation of the livers further demonstrated that caspase-1 activation after MCD feeding was mainly localized to non-parenchymal cells. Caspase-1-knockout (Casp1(-/-)) mice on the MCD diet showed marked reduction in mRNA expression of genes involved in inflammation and fibrogenesis (tumor necrosis factor-α was 7.6-fold greater in WT vs Casp1(-/-) MCD-fed mice; F4/80 was 1.5-fold greater in WT vs Casp1(-/-) MCD-fed mice; α-smooth muscle actin was 3.2-fold greater in WT vs Casp1(-/-) MCD-fed mice; collagen 1-α was 7.6-fold greater in WT vs Casp1(-/-) MCD-fed mice; transforming growth factor-β was 2.4-fold greater in WT vs Casp1(-/-) MCD-fed mice; cysteine- and glycine-rich protein 2 was 3.2-fold greater in WT vs Casp1(-/-) MCD-fed mice). Furthermore, Sirius red staining for hepatic collagen deposition was significantly reduced in Casp1(-/-) MCD-fed mice compared with WT MCD-fed animals. However, serum alanine aminotransferase levels, caspase-3 activity and terminal deoxynucleotidyl transferase dUTP nick-end labeling-positive cells were similar in Casp1(-/-) and WT mice on the MCD diet. Selective Kupffer cell depletion by clodronate injection markedly suppressed MCD-induced caspase-1 activation and protected mice from fibrogenesis and fibrosis associated with this diet. The conclusion of this study is that it uncovers a novel role for caspase-1 in inflammation and fibrosis during NASH development.
    Document Type:
    Reference
    Product Catalog Number:
    Multiple
    Product Catalog Name:
    Multiple
  • Anti-Caspase 1 -2562408

    Document Type:
    Certificate of Analysis
    Lot Number:
    2562408
    Product Catalog Number:
    06-503-I
    Product Catalog Name:
    Anti-Caspase 1 Antibody
  • Anti-Caspase 1 - 2436803

    Document Type:
    Certificate of Analysis
    Lot Number:
    2436803
    Product Catalog Number:
    06-503-I
    Product Catalog Name:
    Anti-Caspase 1 Antibody
  • Anti-Caspase 1 - Q2165954

    Document Type:
    Certificate of Analysis
    Lot Number:
    Q2165954
    Product Catalog Number:
    06-503-I
    Product Catalog Name:
    Anti-Caspase 1 Antibody
  • Anti-Caspase 1 - 4074843

    Document Type:
    Certificate of Analysis
    Lot Number:
    4074843
    Product Catalog Number:
    06-503-I
    Product Catalog Name:
    Anti-Caspase 1 Antibody